Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)

  • Technology appraisal
  • TA1132
  • Published: 

History

Documents created during the development process.

Notes